TiGenix : TiGenix Raises EUR 12 million via a Private Placement of New Ordinary Shares
(Thomson Reuters ONE) -
REGULATED INFORMATION
FOR IMMEDIATE RELEASE
TiGenix Raises EUR 12 million via a Private Placement of New Ordinary Shares
Leuven, Belgium - November 20, 2013, 8.30 a.m. - TiGenix NV (Euronext Brussels:
TIG) today announces that on November 19, 2013, after the market closed, it has
raised EUR 12 million through a private placement of 34.188.034 new ordinary
shares with Gri-Cel S.A., a fully-owned subsidiary of global healthcare company
Grifols S.A., at an issue price of EUR 0.351 per new share. The issue price is
at least equal to the average closing price of TiGenix' share on NYSE Euronext
Brussels over the 30 day period preceding the date on which issuance of the new
shares commenced (i.e. 19 November 2013).
In connection with this capital increase, the Board of Directors disapplied the
preferential subscription rights of existing shareholders for the benefit of
Gri-Cel. The capital increase was decided within the limits of the authorized
share capital in accordance with article 6 of the articles of association of
TiGenix NV. TiGenix does not intend to use the portion of the authorized capital
remaining after issuance of the aforementioned new shares to issue any
additional shares with cancellation of the preferential subscription right of
the existing shareholders, except, as the case may be, for capital increases in
the framework of the issuance of warrants.
The issuance of the new shares is expected to take place on November 22, 2013
provided TiGenix has timely received the proceeds of the private placement from
Gri-Cel. The listing on NYSE Euronext Brussels of the new shares will be
requested. In this respect, TiGenix will prepare and, after approval by the
FSMA, publish a prospectus regarding the admittance of the new shares to trading
on NYSE Euronext Brussels.
TiGenix intends to use the proceeds of the private placement mainly for
advancing the Company's Phase III clinical trial in complex perianal fistulas in
patients with Crohn's disease (Cx601) and for pursuing market access and
reimbursement and advancing the commercial launch and roll out of ChondroCelect
in selected European markets.
It is expected that shortly after closing of the transaction two directors of
TiGenix will be replaced by two directors proposed by Gri-Cel.
TiGenix will in the future offer to Gri-Cel the possibility to evaluate and
negotiate potential partnering opportunities in relation to the development and
the commercialization of TiGenix products other than ChondroCelect.
For more information
Eduardo Bravo Claudia
D'Augusta Hans Herklots
Chief Executive Officer Chief Financial
Officer hans.herklots(at)tigenix.com
eduardo.bravo(at)tigenix.com claudia.daugusta(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company
with a marketed product for cartilage repair, ChondroCelect®, and a strong
pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.
About Grifols
Grifols is a global healthcare company with a 70-year legacy of improving
people's health and well being through the development of life-saving plasma
medicines, hospital pharmacy products and diagnostic technology for clinical
use.
As a leading producer of plasma medicines, Grifols has a presence in more than
100 countries and is the world leader in plasma collection, with 150 plasma
donation centers across the U.S. Grifols is committed to increasing patient
access to its life-saving plasma medicines through significant manufacturing
expansions and the development of new therapeutic applications of plasma
proteins. The company is headquartered in Barcelona, Spain and employs more than
11,000 people worldwide.
In 2012, Grifols' sales exceeded ?2,620 billion. The company's class A shares
are listed on the Spanish Stock Exchange, where they are part of the Ibex-35
(MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information
visit www.grifols.com.
Important information about forward-looking statements
This press release is for information purposes only and is not intended to
constitute, and should not be construed as, an offer to sell or a solicitation
of any offer to buy shares in the share capital of TiGenix NV (the "Company").
This announcement has been issued by and is the sole responsibility of the
Company.
Certain statements in this press release, as well as oral statements that may be
made by the Company or by officers, directors or employees acting on their
behalf relating to the subject matter hereof, may be considered "forward-
looking". Such forward-looking statements are based on current expectations,
and, accordingly, entail and are influenced by various risks and uncertainties.
Forward-looking statements may be identified by references to strategy, plans,
objectives, goals, future events or intentions. Forward-looking statements
involve a number of known and unknown risks, uncertainties and other factors,
many of which are difficult to predict and generally beyond the control of the
Company. Forward-looking statements may and often do differ materially from
actual results. The Company therefore cannot provide any assurance that such
forward-looking statements will materialize. Additional information concerning
risks and uncertainties affecting the business and other factors that could
cause actual results to differ materially from any forward-looking statement is
contained in the Company's Annual Report. Forward-looking statements speak only
as of the date they are made. The Company expressly disclaims any obligation or
undertaking to update, review or revise any forward-looking statement contained
in this announcement whether as a result of new information, future developments
or otherwise.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1744417]
Unternehmensinformation / Kurzprofil:
Datum: 20.11.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 318526
Anzahl Zeichen: 7919
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : TiGenix Raises EUR 12 million via a Private Placement of New Ordinary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
